Chalcogen Bonded Directly To Ring Carbon Of The Five-membered Hetero Ring Patents (Class 514/418)
-
Publication number: 20100197756Abstract: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.Type: ApplicationFiled: April 12, 2010Publication date: August 5, 2010Inventors: Roger Bonnert, Mark Dickinson, Rukhsana Rasul, Hitesh Sanganee, Simon Teague
-
Publication number: 20100197755Abstract: Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.Type: ApplicationFiled: July 14, 2008Publication date: August 5, 2010Inventors: Mohamed Naguib Attala, Philippe Diaz
-
Publication number: 20100197757Abstract: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.Type: ApplicationFiled: April 15, 2010Publication date: August 5, 2010Inventors: Lars Thore BURGDORF, David Bruge, Hartmut Greiner, Maria Kordowicz, Christian Sirrenberg, Frank Zenke
-
Publication number: 20100184768Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: ApplicationFiled: November 12, 2009Publication date: July 22, 2010Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Publication number: 20100179122Abstract: Compounds of Formula (I): are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: June 23, 2006Publication date: July 15, 2010Inventors: Craig W. Lindsley, William H. Leister, Scott E. Wolkenberg
-
Publication number: 20100179187Abstract: This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.Type: ApplicationFiled: January 4, 2010Publication date: July 15, 2010Inventor: Thomas P. Blackburn
-
Publication number: 20100172916Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 9, 2009Publication date: July 8, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
-
Publication number: 20100168101Abstract: The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Agnes BOMBRUN, Patrick Gerber, Dennis Church
-
Publication number: 20100167994Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.Type: ApplicationFiled: March 9, 2010Publication date: July 1, 2010Applicant: GEORGETOWN UNIVERSITYInventors: Jeffrey A. Toretsky, Aykut Üren, Milton Lang Brown, Yali Kong
-
Publication number: 20100168119Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: October 21, 2009Publication date: July 1, 2010Applicant: PHARMORx, Inc.Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20100166674Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20100159004Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.Type: ApplicationFiled: August 4, 2009Publication date: June 24, 2010Inventors: Maryka Quik, Donato Di Monte, J. William Langston
-
Publication number: 20100158842Abstract: A cosmetic and dermatological composition comprises 2, 3-dihydro-4-hydroxy-2-oxo-1-H-indole-3-acetic acid (4-hydroxy-1-oxindole-3-acetic acid) as an active ingredient for use as a melanin inhibitor and as an anti-tyrosinase enzyme inhibitor. This composition is excellent as a skin whitening agent. Since it also has potent antioxidant and anti-irritant activities it is useful in a cosmetic composition for improving hyperpigmentation disorders of the skin.Type: ApplicationFiled: October 9, 2009Publication date: June 24, 2010Inventor: John Jacob WILLE, Jr.
-
Patent number: 7741362Abstract: The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.Type: GrantFiled: October 5, 2004Date of Patent: June 22, 2010Assignee: Siegfried WursterInventors: Jussi Tomperi, Paivi Hautamaki, Harri Salo, Mia Engstrom, Andrei Tauber, Anna-Marja Hoffren, Siegfried Wurster
-
Patent number: 7741360Abstract: The present invention relates to substituted indoles of Formula (I) useful as pharmaceutical compounds for treating respiratory disorders.Type: GrantFiled: May 25, 2007Date of Patent: June 22, 2010Assignee: AstraZeneca ABInventors: Roger Victor Bonnert, Timothy Jon Luker, John Cumming
-
Patent number: 7737172Abstract: Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.Type: GrantFiled: August 9, 2006Date of Patent: June 15, 2010Assignee: President and Fellows of Harvard CollegeInventors: José A. Halperin, Amarnath Natarajan, Huseyin Aktas, Yun-Hua Fan, Han Chen
-
Patent number: 7732479Abstract: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.Type: GrantFiled: August 18, 2005Date of Patent: June 8, 2010Assignee: Tel Aviv University Future Technology Development L.P.Inventors: Ehud Gazit, Tomer Cohen
-
Publication number: 20100137291Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: ApplicationFiled: December 11, 2009Publication date: June 3, 2010Inventors: Richard A. EARL, Maiko EZAWA, Xinqin FANG, David S. GARVEY, Ricky D. GASTON, Subhash P. KHANAPURE, L. Gordon LETTS, Chia-En LIN, Ramani R. RANATUNGA, Stewart K. RICHARDSON, Joseph D. SCHROEDER, Cheri A. STEVENSON, Shiow-Jyi WEY
-
Publication number: 20100130582Abstract: The present invention relates to new indolinone modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 24, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7723382Abstract: The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of a drug and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and X is O, S, SO, SO2, NR13 or PR13 or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B) R—COOZ (B) wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.Type: GrantFiled: August 6, 2003Date of Patent: May 25, 2010Assignee: Nicox S.A.Inventors: Piero del Soldato, Giancarlo Santus, Francesca Benedini
-
Publication number: 20100125098Abstract: The present invention includes compositions and methods for treating disorders of the skin or mucosa resulting from cancer therapies comprising: identifying a patient receiving cancer treatment; and administering to said patient an effective dose of a treated organic/inorganic complex material with an organic dye molecule or derivative thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Russell R. Chianelli, Siddhartha Das
-
Patent number: 7718690Abstract: N-arylsulfonyl-3-aminoalkoxyindoles indole compounds, radioisotopes, stereoisomers, geometric forms, N-oxides, polymorphs and pharmaceutically acceptable salts.Type: GrantFiled: January 6, 2009Date of Patent: May 18, 2010Inventors: Venkata Satya Nirogi Ramakrishna, Vikas Shreekrishna Shirsath, Rama Sastri Kambhampati, Venkata Satya Veerabhadra Vadlamudi Rao, Venkateswarlu Jasti
-
Patent number: 7709521Abstract: The present invention relates to substituted indoles of formula (I) useful as pharmaceutical compounds for treating respiratory disorders.Type: GrantFiled: August 16, 2004Date of Patent: May 4, 2010Assignee: AstraZeneca ABInventors: Roger Victor Bonnert, Anthony Ronald Cook, Timothy Jon Luker, Rukhsana Tasneem Mohammed, Stephen Thom
-
Publication number: 20100105725Abstract: Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.Type: ApplicationFiled: October 26, 2007Publication date: April 29, 2010Inventors: Min Ge, Songnian Lin, Shawn P. Walsh, Lihu Yang, Changyou Zhou
-
Publication number: 20100099683Abstract: Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.Type: ApplicationFiled: October 9, 2009Publication date: April 22, 2010Inventors: Alan E. TOMKINSON, Xi CHEN, Barbara DZIEGIELEWSKA, Alexander D. MACKERELL, Shijun ZHONG, Gerald M. Wilson
-
Patent number: 7696231Abstract: The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).Type: GrantFiled: October 24, 2002Date of Patent: April 13, 2010Assignee: Laboratoires Serono SAInventors: Agnes Bombrun, Patrick Gerber, Denis Church
-
Publication number: 20100087505Abstract: The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, R4, R5, n and m have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.Type: ApplicationFiled: March 14, 2008Publication date: April 8, 2010Applicant: Bracco Imaging S.p.A.Inventors: Aldo Balsamo, Armando Rossello, Elisa Nuti, Elisabetta Orlandini, Tziano Tuccinardi
-
Patent number: 7691895Abstract: Disclosed herein are compounds of Formula (I), (II), and (III) pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.Type: GrantFiled: November 8, 2007Date of Patent: April 6, 2010Assignee: Ligand Pharmaceuticals, Inc.Inventors: Jyun-Hung Chen, E. Adam Kallel, Thomas Lau, Matthew H. McNeill, Todd A. Miller, Bao N. Nguyen, Richard J. Penulian, Dean P. Phillips, Daniel A. Ruppar, Lin Zhi, Jackline E. Dalgard
-
Patent number: 7687535Abstract: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.Type: GrantFiled: May 25, 2004Date of Patent: March 30, 2010Assignee: AstraZeneca ABInventors: Roger Bonnert, Rukhsana Mohammed, Mark Robert Dickinson
-
Patent number: 7683088Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.Type: GrantFiled: January 16, 2007Date of Patent: March 23, 2010Assignee: Schering CorporationInventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Bandarpalle B. Shankar, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Aneta M. Micula, Seong-Heon Kim, De-Yi Yang, Razia Rizvi
-
Publication number: 20100069375Abstract: The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.Type: ApplicationFiled: November 20, 2009Publication date: March 18, 2010Applicant: UCB PHARMA, S.A.Inventors: Jean-Philippe Starck, Benoit Kenda
-
Publication number: 20100069384Abstract: The present invention relates to derivatives of 5-alkyloxy-indolin-2-one, their method of production and their therapeutic applications. These novel derivatives have affinity and selectivity for the V2 receptors of vasopressin (“V2 receptors”) and can therefore constitute active principles of pharmaceutical compositions.Type: ApplicationFiled: June 12, 2009Publication date: March 18, 2010Applicant: SANOFI-AVENTISInventors: Loic FOULON, Pierrick ROCHARD, Claudine SERRADEIL-LE GAL, Gerard VALETTE
-
Publication number: 20100068301Abstract: Disclosed herein are compositions and compounds that combine an inhibitor of 5-lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an agent that itself produces NO in the mammal. Further disclosed herein are strategies for synthesizing such compounds, and methods for testing whether the combination compounds and compositions provide a desired benefit. Also disclosed herein are pharmaceutical compositions and formulations that combine a FLAP inhibitor and an NO modulator. Further described herein are methods for using such compositions and compounds for the treatment of diseases, conditions, and disorders in a mammal, including a human. Such treatment methods include the separate administration of a FLAP inhibitor and a NO modulator to the mammal, and the simultaneous administration of a FLAP inhibitor and a NO modulator to the mammal.Type: ApplicationFiled: November 30, 2007Publication date: March 18, 2010Inventors: John H. Hutchinson, Mustapha Haddach, Mark Moran, Jillian Evans, Nicholas Simon Stock, Jeffrey Roger Roppe
-
Publication number: 20100056601Abstract: Conventional control agents against acarians parasitic on animals do not have sufficient selective toxicity and are hence not safe for the animals to which the control agents are applied. The control agents are not always satisfactory also in control effect and quick-acting properties. Intensive studies were made on the insecticidal activity of N-substituted indole compounds against acarians and on the safety thereof for mammals including pets. As a result, it was found that an N-substituted indole derivative, e.g., 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-(trifluoromethylthio)indole, or 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-(dichlorofluoromethylthio)indole, has high insecticidal activity and quick-acting properties and is lowly toxic to mammals including pets.Type: ApplicationFiled: November 6, 2009Publication date: March 4, 2010Applicant: Nippon Kayaku Kabushiki KaishaInventors: Satoshi Tanabe, Hiroki Hotta, Tetsuya Toya, Katsuhiko Hosoda
-
Publication number: 20100041652Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: ApplicationFiled: October 26, 2009Publication date: February 18, 2010Inventors: Christopher J. Dinsmore, Douglas C. Beshore, Jeffrey M. Bergman, Craig W. Lindsley
-
Patent number: 7662824Abstract: The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.Type: GrantFiled: March 16, 2006Date of Patent: February 16, 2010Assignee: Janssen Pharmaceutica NVInventors: Kristi Leonard, Tianbao Lu, Robert W. Tuman, Dana L. Johnson, Anna C. Maroney, Jan L. Sechler, Richard W. Connors, Richard S. Alexander, Maxwell D. Cummings, Robert A. Galemmo, Thomas P. Markotan
-
Publication number: 20100029646Abstract: The present application discloses prodrugs of substituted 3,3-diphenyl-1,3-dihydro-indol-2-one compounds having the general formula (I). The 4-position of the phenyl moieties and the N-position of the indole represent useful handles for the introduction of particular prodrug groups, in particular those comprising an amino acid moiety. The prodrug compounds are believed to be useful for the treatment of cancer in a mammal, possibly in combination with one or more other chemotherapeutic agents.Type: ApplicationFiled: December 11, 2007Publication date: February 4, 2010Applicant: Topo Target A/SInventors: Mette Knak Christensen, Fredrik Bjoerkling, Martins Ikaunieks, Andrei Zaichenko, Vija Gailite, Einars Loza, Ivars Kalvinsh, Marina Madre
-
Publication number: 20100029699Abstract: The present invention relates to compounds of Formula (I): pharmaceutically acceptable salts thereof, corresponding preparation processes, pharmaceutical formulations and methods for use as inhibitors of matrix metallproteinase enzymes (MMPs).Type: ApplicationFiled: September 1, 2009Publication date: February 4, 2010Inventors: Simon Gaines, Ian Peter Holmes, Stephen Lewis Martin, Setphen Paul Watson
-
Patent number: 7652046Abstract: The present invention comprises methods for the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders through the administration of compounds of formula (I) and formula (II) which are useful as inhibitors of human casein kinase I?. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) as well as methods for their preparation are also disclosed and claimed.Type: GrantFiled: May 22, 2008Date of Patent: January 26, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: David Marc Fink, Yulin Chiang, Nicola Dawn Collar
-
Patent number: 7649011Abstract: Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.Type: GrantFiled: December 22, 2003Date of Patent: January 19, 2010Assignee: Chemocentryx, Inc.Inventors: Anita Melikian, Jennifer Burns, Brian E. McMaster, Thomas Schall, J. J. Wright
-
Patent number: 7645887Abstract: The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.Type: GrantFiled: March 16, 2004Date of Patent: January 12, 2010Assignee: UCB Pharma, S.A.Inventors: Jean-Philippe Starck, Benoît Kenda
-
Patent number: 7645752Abstract: The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.Type: GrantFiled: January 12, 2007Date of Patent: January 12, 2010Assignee: Wyeth LLCInventors: Robert E. McDevitt, Yanfang Li, Albert J. Robichaud, Gavin D. Heffernan, Richard D. Coghlan, Ronald C. Bernotas
-
Publication number: 20100004179Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.Type: ApplicationFiled: June 29, 2009Publication date: January 7, 2010Inventors: Jeffrey A. Toretsky, Aykut Uren, Milton Lang Brown, Yali Kong
-
Publication number: 20100003320Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.Type: ApplicationFiled: June 5, 2009Publication date: January 7, 2010Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte
-
Patent number: 7642281Abstract: This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.Type: GrantFiled: December 8, 2006Date of Patent: January 5, 2010Assignee: Helicon Therapeutics, Inc.Inventor: Thomas P. Blackburn
-
Publication number: 20090326036Abstract: [2-(6-fluoro-1H-indol-3-ylsulfanyl)benzyl]methyl amine and pharmaceutically acceptable salts thereof, provided it is not the free base in a non-crystalline form are provided for the treatment of affective disorders.Type: ApplicationFiled: September 27, 2007Publication date: December 31, 2009Applicant: H. LUNDBECK A/SInventors: Jan Kehler, Karsten Juhl, Neil Anderson
-
Publication number: 20090324580Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.Type: ApplicationFiled: March 9, 2007Publication date: December 31, 2009Applicants: CENIX BIOSCIENCE GMBH, INSTITUTO DE MEDICINA MOLECULAR , FACULDADE DE MEDICINA DA UNIVERSIDADA DE LISBOAInventors: Michael Hannus, Cecilie Martin, Maria M. Mota, Miguel Prudencio, Christina Dias Rodrigues
-
Publication number: 20090318504Abstract: This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.Type: ApplicationFiled: December 15, 2008Publication date: December 24, 2009Inventors: Thomas P. Blackburn, Michael J. Konkel, Lakmal W. Boteju, Ian Jamie Talisman, John M. Wetzel, Mathivanan Packiarajan, Heidi Chen, Hermo Jimenez
-
Patent number: 7632856Abstract: The present invention relates to indolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: GrantFiled: July 14, 2005Date of Patent: December 15, 2009Assignee: UCB Pharma, S.A.Inventors: Benoît Kenda, Jean-Phillipe Starck
-
Publication number: 20090304816Abstract: A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier.Type: ApplicationFiled: December 6, 2006Publication date: December 10, 2009Applicant: CEREUSCIENCE ABInventors: Ludger Grote, Jan Hedner, Kaj Stenlof